Merck’s (MRK) stock declined 2% on Monday after Summit Therapeutics’ (SMMT) investigational bispecific antibody, ivonescimab, outperformed Merck’s blockbuster PD-L1 inhibitor Keytruda in a first-line lung cancer study.SMMT’s Ivonescimab Shows Meaningful Benefit Over MRK’s KeytrudaThe phase III HARMONi-2 study evaluated ivonescimab monotherapy against Keytruda monotherapy as a first-line treatment for PD-L1-positive advanced non-small cell lung cancer (NSCLC). The study was conducted in China with Summit’s c ...